Immuneering is focused on improving patient outcomes by improving a pipeline of oncology and neuroscience product candidates developed using Co.'s translational bioinformatics platform. Co.'s development programs in oncology is focused on providing treatments for patients with solid tumors caused by mutations of the MAPK pathway and mTOR pathways. Co.'s primary product candidate, IMM-1-104, is designed to be a selective dual-mitogen-activated protein kinase kinase inhibitor that further disrupts kinase suppressor of RAS 1 and 2 to modulate the signaling dynamics of the MAPK pathway. In addition to IMM-1-104, Co. has six other oncology programs in the discovery stage. The IMRX average annual return since 2021 is shown above.
The Average Annual Return on the IMRX average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether IMRX average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the IMRX average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|